{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:11:35Z","timestamp":1794856295431,"version":"4.9.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Italian Medicines Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.diabres.2021.108984","type":"journal-article","created":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T05:07:31Z","timestamp":1627103251000},"page":"108984","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"special_numbering":"C","title":["Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial"],"prefix":"10.1016","volume":"178","author":[{"given":"Giuseppe","family":"Della Pepa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizia","family":"Carli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Vetrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Masulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Vaccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Gastaldelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela A.","family":"Rivellese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutgarda","family":"Bozzetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2021.108984_b0005","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2021.108984_b0010","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108984_b0015","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms, and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.diabres.2021.108984_b0020","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1210\/jc.2015-1966","article-title":"High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels","volume":"100","author":"Portillo-Sanchez","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.diabres.2021.108984_b0025","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.diabres.2021.108984_b0030","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-019-1321-x","article-title":"Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts","volume":"17","author":"Alexander","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.diabres.2021.108984_b0035","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.diabres.2021.108984_b0040","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3390\/nu9101065","article-title":"Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals","volume":"9","author":"Della Pepa","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.diabres.2021.108984_b0045","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jhep.2016.10.036","article-title":"Comment to: \u201cEASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease\u201d","volume":"66","author":"Fonseca","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.diabres.2021.108984_b0050","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2021.108984_b0055","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"issue":"18","key":"10.1016\/j.diabres.2021.108984_b0060","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.diabres.2021.108984_b0065","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabres.2021.108984_b0070","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.28960","article-title":"Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges","volume":"65","author":"Musso","year":"2017","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.diabres.2021.108984_b0075","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.2337\/dc05-2445","article-title":"The effect of pioglitazone on the liver: role of adiponectin","volume":"29","author":"Gastaldelli","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108984_b0080","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1365-2265.2010.03811.x","article-title":"Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with Type 2 diabetes: a double tracer OGTT study","volume":"73","author":"Glass","year":"2010","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.diabres.2021.108984_b0085","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/hep.23116","article-title":"Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis","volume":"50","author":"Gastaldelli","year":"2009","journal-title":"Hepatology"},{"issue":"9493","key":"10.1016\/j.diabres.2021.108984_b0090","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2021.108984_b0095","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11892-013-0378-8","article-title":"The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus","volume":"13","author":"Yau","year":"2013","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.diabres.2021.108984_b0100","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s13300-017-0273-4","article-title":"Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis","volume":"8","author":"Filipova","year":"2017","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2021.108984_b0105","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2337\/diacare.25.3.517","article-title":"Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes","volume":"25","author":"Miyazaki","year":"2002","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.diabres.2021.108984_b0110","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/diacare.23.11.1605","article-title":"Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group","volume":"23","author":"Aronoff","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108984_b0115","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/ejhf.1238","article-title":"Risk of heart failure in diabetic patients receiving sulfonylureas","volume":"20","author":"Vaccaro","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10.1016\/j.diabres.2021.108984_b0120","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S2213-8587(17)30317-0","article-title":"Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial","volume":"5","author":"Vaccaro","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.diabres.2021.108984_b0125","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.numecd.2012.09.003","article-title":"Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial","volume":"22","author":"Vaccaro","year":"2012","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.diabres.2021.108984_b0130","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/nu12010101","article-title":"Pasta Consumption and Connected Dietary Habits: Associations with Glucose Control, Adiposity Measures, and Cardiovascular Risk Factors in People with Type 2 Diabetes-TOSCA.IT Study","volume":"12","author":"Vitale","year":"2019","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.diabres.2021.108984_b0135","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1053\/j.gastro.2009.06.005","article-title":"Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors","volume":"137","author":"Kotronen","year":"2009","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.diabres.2021.108984_b0140","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.diabres.2021.108984_b0145","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1111\/jgh.12665","article-title":"Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)","volume":"29","author":"Otgonsuren","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.diabres.2021.108984_b0150","unstructured":"http:\/\/www.dtu.ox.ac.uk\/homacalculator\/ (last accessed on January 2021)"},{"key":"10.1016\/j.diabres.2021.108984_b0155","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2337\/db16-1167","article-title":"Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study","volume":"66","author":"Gastaldelli","year":"2017","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.diabres.2021.108984_b0160","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/dc09-1825","article-title":"Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk","volume":"33","author":"Amato","year":"2010","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2021.108984_b0165","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3803\/EnM.2018.33.1.105","article-title":"Pioglitazone Attenuates Palmitate-Induced Inflammation and Endoplasmic Reticulum Stress in Pancreatic \u03b2-Cells","volume":"33","author":"Hong","year":"2018","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.diabres.2021.108984_b0170","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.2337\/dc13-2480","article-title":"Can a selective PPARgamma modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?","volume":"37","author":"DePaoli","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2021.108984_b0175","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1111\/dom.13843","article-title":"A novel specific peroxisome proliferator-activated receptor gamma (PPARgamma) modulator YR4-42 ameliorates hyperglycaemia and dyslipidaemia and hepatic steatosis in diet-induced obese mice","volume":"21","author":"Huan","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2021.108984_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/5576531","article-title":"Frailty in Nonalcoholic Fatty Liver Cirrhosis: A Comparison with Alcoholic Cirrhosis, Risk Patterns, and Impact on Prognosis","volume":"2021","author":"Skladany","year":"2021","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.diabres.2021.108984_b0185","doi-asserted-by":"crossref","first-page":"e0178473","DOI":"10.1371\/journal.pone.0178473","article-title":"Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage","volume":"12","author":"Masarone","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.diabres.2021.108984_b0190","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2007.04.013","article-title":"Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis","volume":"47","author":"Balas","year":"2007","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.diabres.2021.108984_b0195","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.clpt.6100146","article-title":"Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus","volume":"82","author":"Berria","year":"2007","journal-title":"Clin Pharmacol Ther"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822721003430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822721003430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:20:38Z","timestamp":1759173638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822721003430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":39,"alternative-id":["S0168822721003430"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2021.108984","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2021.108984","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108984"}}